{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T17:15:28Z","timestamp":1788455728913,"version":"build-2803163510"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,9,3]]},"DOI":"10.7759\/cureus.115727","type":"journal-article","created":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T16:22:32Z","timestamp":1788452552000},"source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and Safety of Topical and Systemic Therapies for Atopic Dermatitis in Patients With Skin of Colour: A Systematic Review"],"prefix":"10.7759","author":[{"given":"Muhammad","family":"Waqas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inzamam","family":"Sarwar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirra","family":"Junejo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zohaib","family":"Ansari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ben Alexander","family":"Marshall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12072701","article-title":"Overview of atopic dermatitis in different ethnic groups","volume":"12","author":"Chiricozzi A","year":"2023","unstructured":"Chiricozzi A, Maurelli M, Calabrese L, Peris K, Girolomoni G. Overview of atopic dermatitis in different ethnic groups. J Clin Med. 2023, 12:2701. 10.3390\/jcm12072701","journal-title":"J Clin Med"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1111\/exd.13514","article-title":"Atopic dermatitis in diverse racial and ethnic groups-Variations in epidemiology, genetics, clinical presentation and treatment","volume":"27","author":"Kaufman BP","year":"2018","unstructured":"Kaufman BP, Guttman-Yassky E, Alexis AF. Atopic dermatitis in diverse racial and ethnic groups-Variations in epidemiology, genetics, clinical presentation and treatment. Exp Dermatol. 2018, 27:340-57. 10.1111\/exd.13514","journal-title":"Exp Dermatol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.7573\/dic.2021-12-1","article-title":"Dermatology: how to manage atopic dermatitis in patients with skin of colour","volume":"11","author":"Sachdeva M","year":"2022","unstructured":"Sachdeva M, Joseph M. Dermatology: how to manage atopic dermatitis in patients with skin of colour. Drugs Context. 2022, 11:10.7573\/dic.2021-12-1","journal-title":"Drugs Context"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1093\/ced\/llad162","article-title":"Atopic dermatitis in skin of colour. Part 2: considerations in clinical presentation and treatment options","volume":"48","author":"Gan C","year":"2023","unstructured":"Gan C, Mahil S, Pink A, Rodrigues M. Atopic dermatitis in skin of colour. Part 2: considerations in clinical presentation and treatment options. Clin Exp Dermatol. 2023, 48:1091-101. 10.1093\/ced\/llad162","journal-title":"Clin Exp Dermatol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.36849\/JDD.6609","article-title":"Insights in skin of color patients with atopic dermatitis and the role of skincare in improving outcomes","volume":"21","author":"Alexis A","year":"2022","unstructured":"Alexis A, Woolery-Lloyd H, Andriessen A, Callender V, Gonzalez M, Heath C, Han G. Insights in skin of color patients with atopic dermatitis and the role of skincare in improving outcomes. J Drugs Dermatol. 2022, 21:462-70. 10.36849\/JDD.6609","journal-title":"J Drugs Dermatol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1097\/DER.0000000000000864","article-title":"Assessment and monitoring challenges among patients with moderate-to-severe atopic dermatitis across Fitzpatrick skin types: a photographic review and case series","volume":"33","author":"Aoki V","year":"2022","unstructured":"Aoki V, Oliveira M, Wegzyn C, Desai SR, Jewell S, Ladizinski B, Simpson EL. Assessment and monitoring challenges among patients with moderate-to-severe atopic dermatitis across Fitzpatrick skin types: a photographic review and case series. Dermatitis. 2022, 33:S24-36. 10.1097\/DER.0000000000000864","journal-title":"Dermatitis"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.36849\/JDD.8705","article-title":"Racial and ethnic representation in atopic dermatitis clinical trials","volume":"24","author":"Kabakova M","year":"2025","unstructured":"Kabakova M, Y Wang J, Patel P, Zafar K, Bitterman D, Jagdeo J. Racial and ethnic representation in atopic dermatitis clinical trials. J Drugs Dermatol. 2025, 24:360-4. 10.36849\/JDD.8705","journal-title":"J Drugs Dermatol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2014.1674","article-title":"Efficacy of systemic treatments for atopic dermatitis in racial and ethnic minorities in the United States","volume":"150","author":"Bhattacharya T","year":"2014","unstructured":"Bhattacharya T, Silverberg JI. Efficacy of systemic treatments for atopic dermatitis in racial and ethnic minorities in the United States. JAMA Dermatol. 2014, 150:1232-4. 10.1001\/jamadermatol.2014.1674","journal-title":"JAMA Dermatol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1177\/12034754241260023","article-title":"Response to biologic therapy in skin of colour participants with moderate-to-severe psoriasis and atopic dermatitis: a systematic review","volume":"28","author":"Rijal H","year":"2024","unstructured":"Rijal H, Bouadi N, Abduelmula A, Maliyar K, Bourkas AN, Georgakopoulos JR, Yeung J. Response to biologic therapy in skin of colour participants with moderate-to-severe psoriasis and atopic dermatitis: a systematic review. J Cutan Med Surg. 2024, 28:468-72. 10.1177\/12034754241260023","journal-title":"J Cutan Med Surg"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-025-01489-w","article-title":"Tapinarof cream for adults and children with atopic dermatitis-efficacy by race and Fitzpatrick skin type in two phase 3 randomized clinical trials","volume":"15","author":"Alexis AF","year":"2025","unstructured":"Alexis AF, Kircik L, Chovatiya R, et al.. Tapinarof cream for adults and children with atopic dermatitis-efficacy by race and Fitzpatrick skin type in two phase 3 randomized clinical trials. Dermatol Ther (Heidelb). 2025, 15:2667-82. 10.1007\/s13555-025-01489-w","journal-title":"Dermatol Ther (Heidelb)"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page MJ","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al.. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021, 372:n71. 10.1136\/bmj.n71","journal-title":"BMJ"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l6890","article-title":"Synthesis without meta-analysis (SWiM) in systematic reviews: reporting guideline","volume":"368","author":"Campbell M","year":"2020","unstructured":"Campbell M, McKenzie JE, Sowden A, et al.. Synthesis without meta-analysis (SWiM) in systematic reviews: reporting guideline. BMJ. 2020, 368:l6890. 10.1136\/bmj.l6890","journal-title":"BMJ"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.anai.2023.11.002","article-title":"Abrocitinib efficacy and safety in moderate-to-severe atopic dermatitis by race, ethnicity, and Fitzpatrick skin type","volume":"132","author":"Alexis AF","year":"2024","unstructured":"Alexis AF, Silverberg JI, Rice ZP, et al.. Abrocitinib efficacy and safety in moderate-to-severe atopic dermatitis by race, ethnicity, and Fitzpatrick skin type. Ann Allergy Asthma Immunol. 2024, 132:383-389.e3. 10.1016\/j.anai.2023.11.002","journal-title":"Ann Allergy Asthma Immunol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-019-00450-w","article-title":"Efficacy and safety of crisaborole ointment, 2%, for the treatment of mild-to-moderate atopic dermatitis across racial and ethnic groups","volume":"20","author":"Callender VD","year":"2019","unstructured":"Callender VD, Alexis AF, Stein Gold LF, et al.. Efficacy and safety of crisaborole ointment, 2%, for the treatment of mild-to-moderate atopic dermatitis across racial and ethnic groups. Am J Clin Dermatol. 2019, 20:711-23. 10.1007\/s40257-019-00450-w","journal-title":"Am J Clin Dermatol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.17451","article-title":"Tapinarof cream for the treatment of atopic dermatitis: efficacy and safety results from two Japanese phase 3 trials","volume":"51","author":"Igarashi A","year":"2024","unstructured":"Igarashi A, Tsuji G, Fukasawa S, Murata R, Yamane S. Tapinarof cream for the treatment of atopic dermatitis: efficacy and safety results from two Japanese phase 3 trials. J Dermatol. 2024, 51:1404-13. 10.1111\/1346-8138.17451","journal-title":"J Dermatol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1080\/03007995.2024.2436982","article-title":"Efficacy and safety of lebrikizumab combined with topical corticosteroids in Japanese patients with moderate-to-severe atopic dermatitis: a phase 3, double-blind, placebo-controlled, randomized clinical trial (ADhere-J)","volume":"41","author":"Katoh N","year":"2025","unstructured":"Katoh N, Tanaka A, Takahashi H, et al.. Efficacy and safety of lebrikizumab combined with topical corticosteroids in Japanese patients with moderate-to-severe atopic dermatitis: a phase 3, double-blind, placebo-controlled, randomized clinical trial (ADhere-J). Curr Med Res Opin. 2025, 41:1-12. 10.1080\/03007995.2024.2436982","journal-title":"Curr Med Res Opin"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.36849\/JDD.85852","article-title":"Dupilumab treatment improves lichenification in atopic dermatitis in different age and racial groups","volume":"24","author":"Guttman-Yassky E","year":"2025","unstructured":"Guttman-Yassky E, Katoh N, J Cork M, et al.. Dupilumab treatment improves lichenification in atopic dermatitis in different age and racial groups. J Drugs Dermatol. 2025, 24:167-73. 10.36849\/JDD.85852","journal-title":"J Drugs Dermatol"},{"key":"ref18","article-title":"Efficacy of dupilumab in different racial subgroups of adults with moderate-to-severe atopic dermatitis in three randomized, placebo-controlled phase 3 trials","volume":"18","author":"Alexis AF","year":"2019","unstructured":"Alexis AF, Rendon M, Silverberg JI, et al.. Efficacy of dupilumab in different racial subgroups of adults with moderate-to-severe atopic dermatitis in three randomized, placebo-controlled phase 3 trials. J Drugs Dermatol. 2019, 18:804-13.","journal-title":"J Drugs Dermatol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1002\/hsr2.2165","article-title":"The Cochrane risk of bias assessment tool 2 (RoB 2) versus the original RoB: a perspective on the pros and cons","volume":"7","author":"Nejadghaderi SA","year":"2024","unstructured":"Nejadghaderi SA, Balibegloo M, Rezaei N. The Cochrane risk of bias assessment tool 2 (RoB 2) versus the original RoB: a perspective on the pros and cons. Health Sci Rep. 2024, 7:e2165. 10.1002\/hsr2.2165","journal-title":"Health Sci Rep"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.i4919","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions","volume":"355","author":"Sterne JA","year":"2016","unstructured":"Sterne JA, Hern\u00e1n MA, Reeves BC, et al.. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ. 2016, 355:i4919. 10.1136\/bmj.i4919","journal-title":"BMJ"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1590\/1516-3180.2022.0043.R1.07042022","article-title":"Assessment of the strength of recommendation and quality of evidence: GRADE checklist. A descriptive study","volume":"140","author":"Bezerra CT","year":"2022","unstructured":"Bezerra CT, Grande AJ, Galv\u00e3o VK, Santos DH, Atallah \u00c1N, Silva V. Assessment of the strength of recommendation and quality of evidence: GRADE checklist. A descriptive study. Sao Paulo Med J. 2022, 140:829-36. 10.1590\/1516-3180.2022.0043.R1.07042022","journal-title":"Sao Paulo Med J"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.16792","article-title":"Efficacy and safety of crisaborole ointment in Chinese and Japanese patients aged \u22652\u2009years with mild-to-moderate atopic dermatitis","volume":"50","author":"Ma L","year":"2023","unstructured":"Ma L, Zhang L, Kobayashi M, et al.. Efficacy and safety of crisaborole ointment in Chinese and Japanese patients aged \u22652\u2009years with mild-to-moderate atopic dermatitis. J Dermatol. 2023, 50:847-55. 10.1111\/1346-8138.16792","journal-title":"J Dermatol"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.25251\/32bs1796","article-title":"Once-daily roflumilast cream 0.05% for the treatment of atopic dermatitis in patients aged 2-5 years with diverse skin types: subgroup analysis from the phase 3 INTEGUMENT-PED trial","volume":"10","author":"Prajapati VH","year":"2026","unstructured":"Prajapati VH, Eichenfield LF, Browning JC, et al.. Once-daily roflumilast cream 0.05% for the treatment of atopic dermatitis in patients aged 2-5 years with diverse skin types: subgroup analysis from the phase 3 INTEGUMENT-PED trial. SKIN J Cutan Med. 2026, 10:745. 10.25251\/32bs1796","journal-title":"SKIN J Cutan Med"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.18565","article-title":"Efficacy and safety of dupilumab in Japanese adults with moderate-to-severe atopic dermatitis: a subanalysis of three clinical trials","volume":"183","author":"Katoh N","year":"2020","unstructured":"Katoh N, Kataoka Y, Saeki H, et al.. Efficacy and safety of dupilumab in Japanese adults with moderate-to-severe atopic dermatitis: a subanalysis of three clinical trials. Br J Dermatol. 2020, 183:39-51. 10.1111\/bjd.18565","journal-title":"Br J Dermatol"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdin.2022.09.006","article-title":"Comparison of real-world treatment outcomes of systemic immunomodulating therapy in atopic dermatitis patients with dark and light skin types","volume":"10","author":"Bosma AL","year":"2023","unstructured":"Bosma AL, Ouwerkerk W, Heidema MJ, et al.. Comparison of real-world treatment outcomes of systemic immunomodulating therapy in atopic dermatitis patients with dark and light skin types. JAAD Int. 2023, 10:14-24. 10.1016\/j.jdin.2022.09.006","journal-title":"JAAD Int"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-025-00985-1","article-title":"Efficacy and safety of tralokinumab across racial subgroups in adults with moderate-to-severe atopic dermatitis: post hoc analysis of phase III trials","volume":"27","author":"Mayo T","year":"2026","unstructured":"Mayo T, Silverberg JI, Armstrong A, et al.. Efficacy and safety of tralokinumab across racial subgroups in adults with moderate-to-severe atopic dermatitis: post hoc analysis of phase III trials. Am J Clin Dermatol. 2026, 27:149-66. 10.1007\/s40257-025-00985-1","journal-title":"Am J Clin Dermatol"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-025-00970-8","article-title":"Efficacy and safety of lebrikizumab in adult and adolescent patients with skin of color and moderate-to-severe atopic dermatitis: results from the phase IIIb, open-label ADmirable study","volume":"26","author":"Alexis A","year":"2025","unstructured":"Alexis A, Moiin A, Waibel J, et al.. Efficacy and safety of lebrikizumab in adult and adolescent patients with skin of color and moderate-to-severe atopic dermatitis: results from the phase IIIb, open-label ADmirable study. Am J Clin Dermatol. 2025, 26:803-17. 10.1007\/s40257-025-00970-8","journal-title":"Am J Clin Dermatol"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.19232","article-title":"Upadacitinib for moderate-to-severe atopic dermatitis: stratified analysis from three randomized phase 3 trials by key baseline characteristics","volume":"37","author":"Thyssen JP","year":"2023","unstructured":"Thyssen JP, Tha\u00e7i D, Bieber T, et al.. Upadacitinib for moderate-to-severe atopic dermatitis: stratified analysis from three randomized phase 3 trials by key baseline characteristics. J Eur Acad Dermatol Venereol. 2023, 37:1871-80. 10.1111\/jdv.19232","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-022-00828-5","article-title":"Pooled safety analysis of baricitinib in adult participants with atopic dermatitis in the Japanese subpopulation from six randomized clinical trials","volume":"12","author":"Katoh N","year":"2022","unstructured":"Katoh N, Takita Y, Isaka Y, Nishikawa A, Torisu-Itakura H, Saeki H. Pooled safety analysis of baricitinib in adult participants with atopic dermatitis in the Japanese subpopulation from six randomized clinical trials. Dermatol Ther (Heidelb). 2022, 12:2765-79. 10.1007\/s13555-022-00828-5","journal-title":"Dermatol Ther (Heidelb)"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/519767-efficacy-and-safety-of-topical-and-systemic-therapies-for-atopic-dermatitis-in-patients-with-skin-of-colour-a-systematic-review","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T16:22:32Z","timestamp":1788452552000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/519767-efficacy-and-safety-of-topical-and-systemic-therapies-for-atopic-dermatitis-in-patients-with-skin-of-colour-a-systematic-review"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,3]]},"references-count":29,"URL":"https:\/\/doi.org\/10.7759\/cureus.115727","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9,3]]}}}